| 项目编号 |
PRJCA039535 |
| 项目标题 |
NeoADAURA study EGFR data |
| 涉及领域 |
Medical |
| 数据类型 |
Variation
|
| 物种名称 |
Homo sapiens
|
| 描述信息 |
This is a Phase III, randomised, controlled, multi-centre, 3-arm study of neoadjuvant osimertinib as monotherapy or in combination with chemotherapy, versus SoC chemotherapy alone, for the treatment of patients with EGFRm (Ex19del and/or L858R), resectable NSCLC. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2025-04-29 |
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| AstraZeneca AB
|
|
2021LP00066
|
A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA)
|
|
|
| 提交者 |
JIANXING
HE (drjianxing_he1@126.com)
|
| 提交单位 |
The First Affiliated Hospital of Guangzhou Medical University |
| 提交日期 |
2025-04-29 |
